Ninoxan (Nitrous Oxide, Oxygen)

Nitrous oxide produces its effects by antagonizing N‑methyl‑D‑aspartate (NMDA) receptors in the central nervous system and by modulating endogenous opioid pathways. This dual action reduces pain transmission and produces sedation, while the accompanying oxygen component maintains adequate oxygenation during the procedure.

The dose of Ninoxan is determined by the prescribing clinician based on the patient’s age, weight, clinical condition and the intended level of sedation or anesthesia. The prescriber selects the appropriate flow rate and concentration of nitrous oxide‑oxygen mixture and adjusts it continuously during the procedure.

The safety of nitrous oxide‑oxygen mixtures during pregnancy and lactation has not been definitively established. Use is generally avoided in the first trimester and only considered when the potential benefit outweighs any possible risk. Breastfeeding mothers should consult their healthcare provider before exposure.

To place an order, submit an enquiry on the Ninoxan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with volatile agents such as sevoflurane, nitrous oxide provides rapid onset and offset, minimal metabolism and a lower incidence of airway irritation. However, it offers less depth of anesthesia and is often used in combination with other agents to achieve the desired level of sedation or analgesia.

Ninoxan cylinders should be stored at ambient temperature, away from direct sunlight and heat sources, in a well‑ventilated area. Keep the cylinders upright, secure them to prevent tipping, and ensure the regulator is protected from damage. Follow all local regulations for compressed gas storage.

Ninoxan is delivered through a calibrated vaporizer or a demand‑flow system that mixes nitrous oxide with oxygen. The patient inhales the gas mixture via a face mask or nasal hood, and the clinician adjusts the concentration to achieve the desired analgesic or sedative effect while continuously monitoring vital signs.

The most serious adverse events associated with nitrous oxide‑oxygen inhalation include respiratory depression, hypoxia, cardiovascular instability, malignant hyperthermia and loss of consciousness. Immediate recognition and supportive measures, such as supplemental oxygen and airway management, are essential to mitigate these risks.

Ninoxan is contraindicated in patients with known hypersensitivity to nitrous oxide or oxygen, severe chronic obstructive pulmonary disease, uncontrolled asthma, or those with a history of malignant hyperthermia. It should also be avoided in patients who are unable to protect their airway or who are undergoing procedures requiring complete muscle relaxation without additional neuromuscular blockade.